U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C34H38N4O6.ClH
Molecular Weight 635.15
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEMATOPORPHYRIN MONOHYDROCHLORIDE

SMILES

Cl.CC(O)C1=C(C)C2=CC3=C(C(C)O)C(C)=C(N3)C=C4N=C(C=C5NC(=CC1=N2)C(C)=C5CCC(O)=O)C(CCC(O)=O)=C4C

InChI

InChIKey=MGHOGMAFXGLVGW-IDTMDVKXSA-N
InChI=1S/C34H38N4O6.ClH/c1-15-21(7-9-31(41)42)27-14-28-22(8-10-32(43)44)16(2)24(36-28)12-29-34(20(6)40)18(4)26(38-29)13-30-33(19(5)39)17(3)25(37-30)11-23(15)35-27;/h11-14,19-20,36-37,39-40H,7-10H2,1-6H3,(H,41,42)(H,43,44);1H/b23-11-,24-12-,25-11-,26-13-,27-14-,28-14-,29-12-,30-13-;

HIDE SMILES / InChI
Hematoporphyrin (Photodyn), a porphyrin prepared from hemin, is used as a photosensitizer in photodynamic therapy. Photodynamic therapy is based on the use of light-sensitive photosensitizers. Photoactivation causes the formation of singlet oxygen, which produces peroxidative reactions that can cause cell damage and death. Hematoporphyrin was used as the therapeutic agent in patients with manic-depressive reactions and in patients with involutional melancholia. One of the last studies has shown, that Hematoporphyrin-Photodynamic therapy (PDT) combined with stent placement is an effective and safe treatment for extrahepatic cholangiocarcinoma (EHCC).

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Sources: DOI: 10.1176/ajp.90.6.1157
Primary
Unknown

Approved Use

Unknown
Sources: DOI: 10.1176/ajp.90.6.1157
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The use of hematoporphyrin derivative (HpD) in the localization and treatment of transitional cell carcinoma (TCC) of the bladder.
1984
[Effects of quercetin on photosensitized oxidation of alpha-tocopherol in human blood cells in the presence of hematoporphyrin].
1990
Separation of lipoproteins, albumin and gamma-globulin by single-step ultracentrifugation of human serum. Application. I: Binding of hematoporphyrin to human serum and to albumin.
1995 Apr
Temperature-induced changes in fluorescence properties as a probe of porphyrin microenvironment in lipid membranes. 2. The partition of hematoporphyrin and protoporphyrin in mitochondria.
1995 Oct 1
Structural investigation of the complexation properties between horse spleen apoferritin and metalloporphyrins.
1996 Mar
[Whole bladder wall laser irradiation to prevent bladder cancer recurrence with intravesical HpD and ascorbic acid].
1997 Nov
YC-1-like potentiation of NO-dependent activation of soluble guanylate cyclase by derivatives of protoporphyrin IX.
2006 Mar
Patents

Sample Use Guides

Twenty-three patients with manic-depressive reactions were treated during the depressed phase with intramuscular and oral administration of hematoporphyrin hydrochloride for an average period of 50 to 6o days. Of this number five showed marked sustained improvement, six showed moderate sustained improvement, and six were generally benefited but the course of the psychosis did not seem to be positively affected. Six gave no favorable response. Seventeen patients of 23 can be said to have been definitely helped by the treatment
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
HEMATOPORPHYRIN MONOHYDROCHLORIDE
Common Name English
21H,23H-PORPHINE-2,18-DIPROPANOIC ACID, 7,12-BIS(1-HYDROXYETHYL)-3,8,13,17-TETRAMETHYL-, HYDROCHLORIDE
Common Name English
2,18-PORPHINEDIPROPIONIC ACID, 7,12-BIS(1-HYDROXYETHYL)-3,8,13,17-TETRAMETHYL-, HYDROCHLORIDE
Common Name English
Code System Code Type Description
CAS
17471-45-3
Created by admin on Sat Dec 16 09:42:10 GMT 2023 , Edited by admin on Sat Dec 16 09:42:10 GMT 2023
NON-SPECIFIC STOICHIOMETRY
ECHA (EC/EINECS)
241-486-6
Created by admin on Sat Dec 16 09:42:10 GMT 2023 , Edited by admin on Sat Dec 16 09:42:10 GMT 2023
PRIMARY
PUBCHEM
3084279
Created by admin on Sat Dec 16 09:42:10 GMT 2023 , Edited by admin on Sat Dec 16 09:42:10 GMT 2023
PRIMARY
FDA UNII
R9KB28OL6K
Created by admin on Sat Dec 16 09:42:10 GMT 2023 , Edited by admin on Sat Dec 16 09:42:10 GMT 2023
PRIMARY
CAS
6033-50-7
Created by admin on Sat Dec 16 09:42:10 GMT 2023 , Edited by admin on Sat Dec 16 09:42:10 GMT 2023
PRIMARY